Home
Scholarly Works
A phase I study of nivolumab (anti-PD-1;...
Conference

A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts)

Authors

Rizvi NA; Antonia SJ; Chow LQM; Brahmer JR; Juergens RA; Borghaei H; Shepherd FA; Laurie SA; Gerber DE; Goldman JW

Volume

31

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Publication Date

May 20, 2013

Name of conference

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

Chicago, IL

Conference start date

May 31, 2013

Conference end date

June 4, 2013

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

15

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team